Development of novel therapies for MG: Studies in animal models

References

• Shelton GD. Acquired myasthenia gravis: What we have learned from experimental and spontaneous animal models. Vet Immunol Immunopathol. 1999; 69:239–249.
   PubMed Web of Science ®Google Scholar
• Link H, Xiao BG. Rat models as tool to develop new immunotherapies. Immunol Rev. 2001; 184:117–128.
   PubMed Web of Science ®Google Scholar
• Meinl E, Klinkert WE, Wekerle H. The thymus in myasthenia gravis. Changes typical for the human disease are absent in experimental autoimmune myasthenia gravis of the Lewis rat. Am J Pathol. 1991; 139:995–1008.
   PubMed Web of Science ®Google Scholar
• Lennon VA, Lambert EH, Leiby KR, Okarma TB, Talib S. Recombinant human acetylcholine receptor alpha-subunit induces chronic experimental autoimmune myasthenia gravis. J Immunol. 1991; 146:2245–2248.
   PubMed Web of Science ®Google Scholar
• Shigemoto K, Kubo S, Maruyama N, Hato N, Yamada H, Jie C, Kobayashi N, Mominoki K, Abe Y, Ueda N, Matsuda S. Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest. 2006; 116:1016–1024.
   PubMed Web of Science ®Google Scholar
• Jha S, Xu K, Maruta T, Oshima M, Mosier DR, Atassi MZ, Hoch W. Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK). J Neuroimmunol. 2006; 175:107–117.
   PubMed Web of Science ®Google Scholar
• Aissaoui A, Klingel-Schmitt I, Couderc J, Chateau D, Romagne F, Jambou F, Vincent A, Levasseur P, Eymard B, Maillot MC, Galanaud P, Berrih-Aknin S, Cohen-Kaminsky S. Prevention of autoimmune attack by targeting specific T-cell receptors in a severe combined immunodeficiency mouse model of myasthenia gravis. Ann Neurol. 1999; 46:559–567.
   PubMed Web of Science ®Google Scholar
• Schonbeck S, Padberg F, Hohlfeld R, Wekerle H. Transplantation of thymic autoimmune microenvironment to severe combined immunodeficiency mice. A new model of myasthenia gravis. J Clin Invest. 1992; 90:245–250.
   PubMed Web of Science ®Google Scholar
• Bartfeld D, Fuchs S. Specific immunosuppression of experimental autoimmune myasthenia gravis by denatured acetylcholine receptor. Proc Natl Acad Sci USA. 1978; 75:4006–4010.
   PubMed Web of Science ®Google Scholar
• Weiner HL. Oral tolerance: Immune mechanisms and treatment of autoimmune diseases. Immunol Today. 1997; 18:335–343.
   PubMedGoogle Scholar
• Toussirot EA. Oral tolerance in the treatment of rheumatoid arthritis. Curr Drug Targets Inflamm Allergy. 2002; 1:45–52.
   PubMedGoogle Scholar
• Wang ZY, Qiao J, Link H. Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor. J Neuroimmunol. 1993; 44:209–214.
   PubMed Web of Science ®Google Scholar
• Okumura S, McIntosh K, Drachman DB. Oral administration of acetylcholine receptor: Effects on experimental myasthenia gravis. Ann Neurol. 1994; 36:704–713.
   PubMed Web of Science ®Google Scholar
• Ma CG, Zhang GX, Xiao BG, Link J, Olsson T, Link H. Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor. J Neuroinimunol. 1995; 58:51–60.
   PubMed Web of Science ®Google Scholar
• Drachman DB, Okumura S, Adams RN, McIntosh KR. Oral tolerance in myasthenia gravis. Ann NY Acad Sci. 1996; 778:258–272.
   PubMed Web of Science ®Google Scholar
• Shi FD, Bai XF, Li HL, Huang YM, Van der Meide PH, Link H. Nasal tolerance in experimental autoimmune myasthenia gravis (EAMG): Induction of protective tolerance in primed animals. Clin Exp Immunol. 1998; 111:506–512.
   Google Scholar
• Tzartos SJ, Lindstrom JM. Monoclonal antibodies used to probe acetylcholine receptor structure: Localization of the main immunogenic region and detection of similarities between subunits. Proc Natl Acad Sci USA. 1980; 77:755–759.
   PubMed Web of Science ®Google Scholar
• Im SH, Barchan D, Fuchs S, Souroujon MC. Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment. J Clin Invest. 1999; 104:1723–1730.
   PubMed Web of Science ®Google Scholar
• Barchan D, Souroujon MC, Im SH, Antozzi C, Fuchs S. Antigen-specific modulation of experimental myasthenia gravis: Nasal tolerization with recombinant fragments of the human acetylcholine receptor alpha-subunit. Proc Natl Acad Sci USA. 1999; 96:8086–8091.
   PubMed Web of Science ®Google Scholar
• Im SH, Barchan D, Fuchs S, Souroujon MC. Mechanism of nasal tolerance induced by a recombinant fragment of acetylcholine receptor for treatment of experimental myasthenia gravis. J Neuroimmunol. 2000; 111:161–168.
   PubMed Web of Science ®Google Scholar
• Maiti PK, Feferman T, Im SH, Souroujon MC, Fuchs S. Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment. J Neuroimmunol. 2004; 152:112–120.
   PubMed Web of Science ®Google Scholar
• Barchan D, Asher O, Tzartos SJ, Fuchs S, Souroujon MC. Modulation of the anti-acetylcholine receptor response and experimental autoimmune myasthenia gravis by recombinant fragments of the acetylcholine receptor. Eur J Immunol. 1998; 28:616–624.
   PubMed Web of Science ®Google Scholar
• Yi HJ, Chae CS, So JS, Tzartos SJ, Souroujon MC, Fuchs S, Im SH. Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor. Mol Immunol. 2008; 46:192–201.
   PubMed Web of Science ®Google Scholar
• Souroujon MC, Carmon S, Fuchs S. Modulation of anti-acetylcholine receptor antibody specificities and of experimental autoimmune myasthenia gravis by synthetic peptides. Immunol Lett. 1992; 34:19–25.
   PubMed Web of Science ®Google Scholar
• Souroujon MC, Carmon S, Fuchs S. Regulation of experimental autoimmune myasthenia grayis by synthetic peptides of the acetylcholine receptor. Ann NY Acad Sci. 1993; 681:332–334.
   PubMed Web of Science ®Google Scholar
• Atassi MZ, Ruan KH, Jinnai K, Oshima M, Ashizawa T. Epitope-specific suppression of antibody response in experimental autoimmune myasthenia gravis by a monomethoxypolyethylene glycol conjugate of a myasthenogenic synthetic peptide. Proc Natl Acad Sci USA. 1992; 89:5852–5856.
   PubMed Web of Science ®Google Scholar
• Wu B, Deng C, Goluszko E, Christadoss P. Tolerance to a dominant T cell epitope in the acetylcholine receptor molecule induces epitope spread and suppresses murine myasthenia gravis. J Immunol. 1997; 159:3016–3023.
   PubMed Web of Science ®Google Scholar
• Karachunski PI, Ostlie NS, Okita DK, Garman R, Conti-Fine BM. Subcutaneous administration of T-epitope sequences of the acetylcholine receptor prevents experimental myasthenia gravis. J Neuroimmunol. 1999; 93:108–121.
   PubMed Web of Science ®Google Scholar
• Shenoy M, Oshima M, Atassi MZ, Christadoss P. Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region alpha 146–162 of acetylcholine receptor. Clin Immunol Immunopathol. 1993; 66:230–238.
   PubMedGoogle Scholar
• Karachunski PI, Ostlie NS, Okita DK, Conti-Fine BM. Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences. J Clin Invest. 1997; 100:3027–3035.
   PubMed Web of Science ®Google Scholar
• Baggi F, Andreetta F, Caspani E, Milani M, Longhi R, Mantegazza R, Cornelio F, Antozzi C. Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis. J Clin Invest. 1999; 104:1287–1295.
   PubMed Web of Science ®Google Scholar
• Deng C, Goluszko E, Christadoss P. Fas/Fas ligand pathway, apoptosis, and clonal anergy involved in systemic acetylcholine receptor T cell epitope tolerance. J Immunol. 2001; 166:3458–3467.
   PubMed Web of Science ®Google Scholar
• Souroujon MC, Maiti PK, Feferman T, Im SH, Raveh L, Fuchs S. Suppression of myasthenia gravis by antigen-specific mucosal tolerance and modulation of cytokines and costimulatory factors. Ann NY Acad Sci. 2003; 998:533–536.
   PubMed Web of Science ®Google Scholar
• Gautam M, Noakes PG, Mudd J, Nichol M, Chu GC, Sanes JR, Merlie JP. Failure of postsynaptic specialization to develop at neuromuscular junctions of rapsyn-deficient mice. Nature. 1995; 377:232–236.
   PubMed Web of Science ®Google Scholar
• Im SH, Barchan D, Souroujon MC, Fuchs S. Role of tolerogen conformation in induction of oral tolerance in experimental autoimmune myasthenia gravis. J Immunol. 2000; 165:3599–3605.
   PubMed Web of Science ®Google Scholar
• Venkatesh N, Im SH, Balass M, Fuchs S, Katchalski-Katzir E. Prevention of passively transferred experimental autoimmune myasthenia gravis by a phage library-derived cyclic peptide. Proc Natl Acad Sci USA. 2000; 97:761–766.
   PubMedGoogle Scholar
• Im SH, Barchan D, Feferman T, Raveh L, Souroujon MC, Fuchs S. Protective molecular mimicry in experimental myasthenia gravis. J Neuroimmunol. 2002; 126:99–106.
   Google Scholar
• Sela M, Mozes E. Therapeutic vaccines in autoimmunity. Proc Natl Acad Sci USA. 2004; 101 Suppl 2: 14586–14592.
   Google Scholar
• Ben-David H, Sharabi A, Dayan M, Sela M, Mozes E. The role of CD8+CD28 regulatory cells in suppressing myasthenia gravis-associated responses by a dual altered peptide ligand. Proc Natl Acad Sci USA. 2007; 104:17459–17464.
   PubMed Web of Science ®Google Scholar
• Aruna BV, Ben-David H, Sela M, Mozes E. A dual altered peptide ligand down-regulates myasthenogenic T cell responses and reverses experimental autoimmune myasthenia gravis via up-regulation of Fas–FasL-mediated apoptosis. Immunology. 2006; 118:413–424.
   PubMed Web of Science ®Google Scholar
• Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: Implications for immunotherapy. Nat Rev Immunol. 2002; 2:85–95.
   PubMed Web of Science ®Google Scholar
• Feferman T, Im SH, Fuchs S, Souroujon MC. Breakage of tolerance to hidden cytoplasmic epitopes of the acetylcholine receptor in experimental autoimmune myasthenia gravis. J Neuroimmunol. 2003; 140:153–158.
   PubMed Web of Science ®Google Scholar
• Souroujon MC, Barchan D, Fuchs S. Analysis and modulation of the immune response of mice to acetylcholine receptor by anti-idiotypes. Immunol Lett. 1985; 9:331–336.
   PubMed Web of Science ®Google Scholar
• Souroujon MC, Pachner AR, Fuchs S. The treatment of passively transferred experimental myasthenia with anti-idiotypic antibodies. Neurology. 1986; 36:622–625.
   PubMed Web of Science ®Google Scholar
• Araga S, LeBoeuf RD, Blalock JE. Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor. Proc Natl Acad Sci USA. 1993; 90:8747–8751.
   PubMed Web of Science ®Google Scholar
• Loutrari H, Kokla A, Tzartos SJ. Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor. Eur J Immunol. 1992; 22:2449–2452.
   PubMed Web of Science ®Google Scholar
• Araga S, Galin FS, Kishimoto M, Adachi A, Blalock JB. Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors. J Immunol. 1996; 157:386–392.
   PubMed Web of Science ®Google Scholar
• Verschuuren JJ, Graus YM, Van Breda Vriesman PJ, Tzartos S, De Baets MH. In vivo effects of neonatal administration of antiidiotype antibodies on experimental autoimmune myasthenia gravis. Autoimmunity. 1991; 10:173–179.
   PubMed Web of Science ®Google Scholar
• Tzartos SJ, Bitzopoulou K, Gavra I, Kordas G, Jacobson L, Kostelidou K, Lagoumintzis G, Lazos O, Poulas K, Sideris S, Sotiriadis A, Trakas N, Zisimopoulou P. Antigen-specific apheresis of pathogenic autoantibodies from myasthenia gravis sera. Ann NY Acad Sci. 2008; 1132:291–299.
   PubMed Web of Science ®Google Scholar
• Berrih S, Morel E, Gaud C, Raimond F, Le Brigand H, Bach JF. Anti-AChR antibodies, thymic histology, and T cell subsets in myasthenia gravis. Neurology. 1984; 34:66–71.
   PubMed Web of Science ®Google Scholar
• Truffault F, Cohen-Kaminsky S, Khalil I, Levasseur P, Berrih-Aknin S. Altered intrathymic T-cell repertoire in human myasthenia gravis. Ann Neurol. 1997; 41:731–741.
   PubMed Web of Science ®Google Scholar
• Xu L, Villain M, Galin FS, Araga S, Blalock JE. Prevention and reversal of experimental autoimmune myasthenia gravis by a monoclonal antibody against acetylcholine receptor-specific T cells. Cell Immunol. 2001; 208:107–114.
   PubMed Web of Science ®Google Scholar
• Oshima M, Maruta T, Ohtani M, Deitiker PR, Mosier D, Atassi MZ. Vaccination with a MHC class II peptide in Alum and inactive pertussis strongly ameliorates clinical MG in C57BL/6 mice. J Neuroimmunol. 2006; 171:8–16.
   PubMed Web of Science ®Google Scholar
• Oshima M, Deitiker P, Atassi MZ. Targeting the antigen-binding site of HLA-restricting alleles in treatment of autoimmune disease. Crit Rev Immunol. 2007; 27:271–288.
   Google Scholar
• Fattorossi A, Battaglia A, Buzzonetti A, Ciaraffa F, Scambia G, Evoli A. Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: Effect of immunosuppressive treatment. Immunology. 2005; 116:134–141.
   PubMed Web of Science ®Google Scholar
• Sun Y, Qiao J, Lu CZ, Zhao CB, Zhu XM, Xiao BG. Increase of circulating CD4+CD25+T cells in myasthenia gravis patients with stability and thymectomy. Clin Immunol. 2004; 112:284–289.
   PubMed Web of Science ®Google Scholar
• Luther C, Poeschel S, Varga M, Melms A, Tolosa E. Decreased frequency of intrathymic regulatory T cells in patients with myasthenia-associated thymoma. J Neuroimmunol. 2005; 164:124–128.
   Google Scholar
• Balandina A, Lecart S, Dartevelle P, Saoudi A, Berrih-Aknin S. Functional defect of regulatory CD4(+)CD25+T cells in the thymus of patients with autoimmune myasthenia gravis. Blood. 2005; 105:735–741.
   PubMed Web of Science ®Google Scholar
• Wang W, Milani M, Ostlie N, Okita D, Agarwal RK, Caspi RR, Conti-Fine BM. C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells. J Immunol. 2007; 178:7072–7080.
   PubMed Web of Science ®Google Scholar
• Shi FD, Li H, Wang H, Bai X, van der Meide PH, Link H, Ljunggren HG. Mechanisms of nasal tolerance induction in experimental autoimmune myasthenia gravis: Identification of regulatory cells. J Immunol. 1999; 162:5757–5763.
   Google Scholar
• Sheng JR, Li L, Ganesh BB, Vasu C, Prabhakar BS, Meriggioli MN. Suppression of experimental autoimmune myasthenia gravis by granulocyte-macrophage colony-stimulating factor is associated with an expansion of Foxp3+ regulatory T cells. J Immunol. 2006; 177:5296–5306.
   PubMed Web of Science ®Google Scholar
• Liu R, La Cava A, Bai XF, Jee Y, Price M, Campagnolo DI, Christadoss P, Vollmer TL, Van Kaer L, Shi FD. Cooperation of invariant NKT cells and CD4+CD25+T regulatory cells in the prevention of autoimmune myasthenia. J Immunol. 2005; 175:7898–7904.
   PubMed Web of Science ®Google Scholar
• Ben-David H, Aruna BV, Seger R, Sela M, Mozes E. A 50-kDa ERK-like protein is up-regulated by a dual altered peptide ligand that suppresses myasthenia gravis-associated responses. Proc Natl Acad Sci USA. 2006; 103:18232–18237.
   Google Scholar
• Aricha R, Feferman T, Souroujon MC, Fuchs S. Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: Suppression of disease by a phosphodiesterase inhibitor. FASEB J. 2006; 20:374–376.
   PubMed Web of Science ®Google Scholar
• Zhang GX, Xiao BG, Yu LY, van der Meide PH, Link H. Interleukin 10 aggravates experimental autoimmune myasthenia gravis through inducing Th2 and B cell responses to AChR. J Neuroimmunol. 2001; 113:10–18.
   PubMed Web of Science ®Google Scholar
• Aricha R, Feferman T, Fuchs S, Souroujon MC. Ex vivo generated regulatory T cells modulate experimental autoimmune myasthenia gravis. J Immunol. 2008; 180:2132–2139.
   PubMed Web of Science ®Google Scholar
• Sheng JR, Li LC, Ganesh BB, Prabhakar BS, Meriggioli MN. Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia gravis. Clin Immunol. 2008; 128:172–180.
   PubMed Web of Science ®Google Scholar
• Meriggioli MN, Sheng JR, Li L, Prabhakar BS. Strategies for treating autoimmunity: Novel insights from experimental myasthenia gravis. Ann NY Acad Sci. 2008; 1132:276–282.
   PubMed Web of Science ®Google Scholar
• Xiao BG, Duan RS, Link H, Huang YM. Induction of peripheral tolerance to experimental autoimmune myasthenia gravis by acetylcholine receptor-pulsed dendritic cells. Cell Immunol. 2003; 223:63–69.
   PubMed Web of Science ®Google Scholar
• Yarilin D, Duan R, Huang YM, Xiao BG. Dendritic cells exposed in vitro to TGF-betal ameliorate experimental autoimmune myasthenia gravis. Clin Exp Immunol. 2002; 127:214–219.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang Y. Neural-immune communication in Caenorhabditis elegans. Cell Host Microbe. 2009; 5:425–429.
   Google Scholar
• Duan RS, Adikari SB, Huang YM, Link H, Xiao BG. Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells. Neurobiol Dis. 2004; 16:461–467.
   PubMed Web of Science ®Google Scholar
• Kong QF, Sun B, Wang GY, Zhai DX, Mu LL, Wang DD, Wang JH, Li R, Li HL. BM stromal cells ameliorate experimental autoimmune myasthenia gravis by altering the balance of Th cells through the secretion of IDO. Eur J Immunol. 2009; 39:800–809.
   PubMed Web of Science ®Google Scholar
• Christadoss P. C5 gene influences the development of murine myasthenia gravis. J Immunol. 1988; 140:2589–2592.
   PubMed Web of Science ®Google Scholar
• Christadoss P, Tuzun E, Li J, Saini SS, Yang H. Classical complement pathway in experimental autoimmune myasthenia gravis pathogenesis. Ann NY Acad Sci. 2008; 1132:210–219.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Gong B, Lin F, Rother RP, Medof ME, Kaminski HJ. Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis. J Immunol. 2007; 179:8562–8567.
   PubMed Web of Science ®Google Scholar
• Soltys J, Kusner LL, Young A, Richmonds C, Hatala D, Gong B, Shanmugavel V, Kaminski HJ. Novel complement inhibitor limits severity of experimentally myasthenia gravis. Ann Neurol. 2009; 65:67–75.
   PubMed Web of Science ®Google Scholar
• Im SH, Barchan D, Maiti PK, Raveh L, Souroujon MC, Fuchs S. Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18. FASEB J. 2001; 15:2140–2148.
   PubMed Web of Science ®Google Scholar
• Im SH, Barchan D, Maiti PK, Fuchs S, Souroujon MC. Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4. J Immunol. 2001; 166:6893–6898.
   PubMed Web of Science ®Google Scholar
• Duan RS, Wang HB, Yang JS, Scallon B, Link H, Xiao BG. Anti-TNF-alpha antibodies suppress the development of experimental autoimmune myasthenia gravis. J Autoimmun. 2002; 19:169–174.
   PubMed Web of Science ®Google Scholar
• Yang H, Tuzun E, Alagappan D, Yu X, Scott BG, Ischenko A, Christadoss P. IL-1 receptor antagonist-mediated therapeutic effect in murine myasthenia gravis is associated with suppressed serum proinflammatory cytokines, C3, and anti-acetylcholine receptor IgGl. J Immunol. 2005; 175:2018–2025.
   PubMed Web of Science ®Google Scholar
• Le Panse R, Cizeron-Clairac G, Cuvelier M, Truffault F, Bismuth J, Nancy P, De Rosbo NK, Berrih-Aknin S. Regulatory and pathogenic mechanisms in human autoimmune myasthenia gravis. Ann NY Acad Sci. 2008; 1132:135–142.
   Google Scholar
• Le Panse R, Cizeron-Clairac G, Bismuth J, Berrih-Aknin S. Microarrays reveal distinct gene signatures in the thymus of seropositive and seronegative myasthenia gravis patients and the role of CC chemokine ligand 21 in thymic hyperplasia. J Immunol. 2006; 177:7868–7879.
   Google Scholar
• Souroujon MC, Feferman T, Berrih-Aknin S, Fuchs S. Chemokines and chemokine receptors in MG and EAMG. In: Christadoss P, editors. Myasthenia gravis: Disease mechanisms and immune intervention. Linus Publishing Inc; 2009, in press.
   Google Scholar
• Feferman T, Maiti PK, Berrih-Aknin S, Bismuth J, Bidault J, Fuchs S, Souroujon MC. Overexpression of IFN-induced protein l0 and its receptor CXCR3 in myasthenia gravis. J Immunol. 2005; 174:5324–5331.
   Google Scholar
• Feferman T, Aricha R, Mizrachi K, Geron E, Alon R, Souroujon MC, Fuchs S. Suppression of experimental autoimmune myasthenia gravis by inhibiting the signaling between IFN-gamma inducible protein 10 (IP-10) and its receptor CXCR3. J Neuroimmunol. 2009; 209:87–95.
   PubMed Web of Science ®Google Scholar
• Menon RT, Feferman T, Aricha R, Souroujon MC, Fuchs S. Suppression of experimental autoimmune myasthenia gravis by combination therapy: Pentoxifylline as a steroid-sparing agent. J Neuroimmunol. 2008; 201–202:128–135.
   Google Scholar
• Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001; 345:747–755.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: Evidence-based indications and safety profile. Pharmacol Ther. 2004; 102:177–193.
   PubMed Web of Science ®Google Scholar
• Lemieux R, Bazin R, Neron S. Therapeutic intravenous immunoglobulins. Mol Immunol. 2005; 42:839–848.
   PubMed Web of Science ®Google Scholar
• Zhu KY, Feferman T, Maiti PK, Souroujon MC, Fuchs S. Intravenous immunoglobulin suppresses experimental myasthenia gravis: Immunological mechanisms. J Neuroimmunol. 2006; 176:187–197.
   PubMed Web of Science ®Google Scholar
• Fuchs S, Feferman T, Zhu KY, Meidler R, Margalit R, Wang N, Laub O, Souroujon MC. Suppression of experimental autoimmune myasthenia gravis by intravenous immunoglobulin and isolation of a disease-specific IgG fraction. Ann NY Acad Sci. 2007; 1110:550–558.
   Google Scholar
• Fuchs S, Feferman T, Meidler R, Brenner T, Laub O, Souroujon MC. The disease-specific arm of the therapeutic effect of intravenous immunoglobulin in autoimmune diseases: Experimental autoimmune myasthenia gravis as a model. Isr Med Assoc J. 2008; 10:58–60.
   Google Scholar
• Fuchs S, Feferman T, Meidler R, Margalit R, Sicsic C, Wang N, Zhu KY, Brenner T, Laub O, Souroujon MC. A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis. J Neuroimmunol. 2008; 194:89–96.
   Google Scholar
• Brenner T, Abramsky O, Lisak RP. Influence of alpha-fetoprotein on the in vitro and in vivo immune response to acetylcholine receptor. Ann NY Acad Sci. 1981; 377:208–221.
   Google Scholar
• Brenner T, Abramsky O. Immunosuppression of experimental autoimmune myasthenia gravis by alpha-fetoprotein rich formation. Immunol Lett. 1981; 3:163–167.
   PubMed Web of Science ®Google Scholar
• Brenner T, Zielinski A, Argov Z, Abramsky O. Prevention of experimental autoimmune myasthenia gravis in rats by fetal alpha-fetoprotein-rich fractions. Tumour Biol. 1984; 5:263–274.
   Google Scholar
• Schneider-Gold C, Hartung HP, Gold R. Mycophenolate mofetil and tacrolimus: New therapeutic options in neuroimmunological diseases. Muscle Nerve. 2006; 34:284–291.
   PubMed Web of Science ®Google Scholar
• Sathasivam S. Steroids and immunosuppressant drugs in myasthenia gravis. Nat Clin Pract Neurol. 2008; 4:317–327.
   Google Scholar
• Janssen SP, Phernambucq M, Martinez-Martinez P, De Baets MH, Losen M. Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil. J Neuroimmunol. 2008; 201–202:111–120.
   Google Scholar
• Ubiali F, Nava S, Nessi V, Longhi R, Pezzoni G, Capobianco R, Mantegazza R, Antozzi C, Baggi F. Pixantrone (BBR2778) reduces the severity of experimental autoimmune myasthenia gravis in Lewis rats. J Immunol. 2008; 180:2696–2703.
   PubMed Web of Science ®Google Scholar
• Karussis DM, Lehmann D, Brenner T, Wirguin I, Mizrachi-Koll R, Sicsic C, Abramsky O. Immunomodulation of experimental autoimmune myasthenia gravis with linomide. J Neuroimmunol. 1994; 55:187–193.
   PubMed Web of Science ®Google Scholar
• Linker RA, Kieseier BC, Gold R. Identification and development of new therapeutics for multiple sclerosis. Trends Pharmacol Sci. 2008; 29:558–565.
   PubMed Web of Science ®Google Scholar
• Liu L, Garcia AM, Santoro H, Zhang Y, McDonnell K, Dumont J, Bitonti A. Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade. J Immunol. 2007; 178:5390–5398.
   PubMed Web of Science ®Google Scholar
• Soreq H, Seidman S. Acetylcholinesterase—new roles for an old actor. Nat Rev Neurosci. 2001; 2:294–302.
   PubMed Web of Science ®Google Scholar
• Behra M, Cousin X, Bertrand C, Vonesch JL, Biellmann D, Chatonnet A, Strahle U. Acetylcholinesterase is required for neuronal and muscular development in the zebrafish embryo. Nat Neurosci. 2002; 5:111–118.
   PubMed Web of Science ®Google Scholar
• Brenner T, Hamra-Amitay Y, Evron T, Boneva N, Seidman S, Soreq H. The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis. FASEB J. 2003; 17:214–222.
   PubMed Web of Science ®Google Scholar
• Boneva N, Hamra-Amitay Y, Wirguin I, Brenner T. Stimulated-single fiber electromyography monitoring of anti-sense induced changes in experimental autoimmune myasthenia gravis. Neurosci Res. 2006; 55:40–44.
   PubMed Web of Science ®Google Scholar
• Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang H, Abumfad N, Eaton JW, Tracey KJ. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 2000; 405:458–462.
   PubMed Web of Science ®Google Scholar
• de Jonge WJ, Ulloa L. The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. Br J Pharmacol. 2007; 151:915–929.
   PubMed Web of Science ®Google Scholar
• Nizri E, Hamra-Amitay Y, Sicsic C, Lavon I, Brenner T. Anti-inflammatory properties of cholinergic up-regulation: A new role for acetylcholinesterase inhibitors. Neuropharmacology. 2006; 50:540–547.
   PubMed Web of Science ®Google Scholar
• Brenner T, Nizri E, Irony-Tur-Sinai M, Hamra-Amitay Y, Wirguin I. Acetylcholinesterase inhibitors and cholinergic modulation in myasthenia gravis and neuroinflammation. J Neuroimmunol. 2008; 201–202:121–127.
   PubMed Web of Science ®Google Scholar
• Argov Z, McKee D, Agus S, Brawer S, Shlomowitz N, Yoseph OB, Soreq H, Sussman JD. Treatment of human myasthenia gravis with oral antisense suppression of acetylcholinesterase. Neurology. 2007; 69:699–700.
   PubMed Web of Science ®Google Scholar
• Kaminski HJ. Restoring balance at the neuromuscular junction. Neurology. 2007; 69:629–630.
   Google Scholar
• Cartaud A, Coutant S, Petrucci TC, Cartaud J. Evidence for in situ and in vitro association between beta-dystroglycan and the subsynaptic 43K rapsyn protein. Consequence for acetylcholine receptor clustering at the synapse. J Biol Chem. 1998; 273:11321–11326.
   PubMed Web of Science ®Google Scholar
• Rybakova IN, Humston JL, Sonnemann KJ, Ervasti JM. Dystrophin and utrophin bind actin through distinct modes of contact. J Biol Chem. 2006; 281:9996–10001.
   PubMed Web of Science ®Google Scholar
• Hoedemaekers A, Bessereau JL, Graus Y, Guyon T, Changeux JP, Berrih-Aknin S, van Breda Vriesman P, De Baets MH. Role of the target organ in determining susceptibility to experimental autoimmune myasthenia gravis. J Neuroimmunol. 1998; 89:131–141.
   Google Scholar
• Hoedemaekers A, Graus Y, van Breda Vriesman P, de Baets M. Age-and sex-related resistance to chronic experimental autoimrmine myasthenia gravis (EAMG) in Brown Norway rats. Clin Exp Immunol. 1997; 107:189–197.
   Google Scholar
• Losen M, Stassen MH, Martinez-Martinez P, Machiels BM, Duimel H, Frederik P, Veldman H, Wokke JH, Spaans F, Vincent A, De Baets MH. Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis. Brain. 2005; 128:2327–2337.
   Google Scholar
• Martinez-Martinez P, Losen M, Duimel H, Frederik P, Spaans F, Molenaar P, Vincent A, De Baets MH. Overexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis. Am J Pathol. 2007; 170:644–657.
   Google Scholar